Eccogene’s Oral GLP-1 Debut, Novo’s 24% Weight Loss Win, Lilly’s Q3 Reveal & More
In this week’s Obesity Updates, we spotlight the latest breakthroughs and strategic shifts transforming obesity treatment—ranging from high-impact GLP-1 data to billion-dollar national research investments and the race for the first obesity vaccine.
🔬 Key Highlights This Week:
💊 Eccogene & AstraZeneca launch Phase 1b trial of once-daily oral GLP-1RA in China
🧪 Novo Nordisk’s Amycretin shows up to 24.3% weight loss—heads straight into Phase III
📊 Eli Lilly prepares Q3 2025 release of Phase 3 data on oral obesity pill Orforglipron
🇨🇳 Sciwind’s Ecnoglutide delivers up to 15.4% weight loss—rivals Wegovy in Phase 3 China trial
🇸🇪 Sweden commits over $18M to a decade-long obesity and metabolic research program
🇮🇳 Utopia Therapeutics raises $1.5M to advance a first-in-class obesity vaccine candidate
Whether you’re a researcher, investor, or life sciences leader, this episode keeps you at the forefront of obesity drug innovation and strategic shifts.
📢 Stay Ahead in Obesity Research!
✅ Like, share, and subscribe for weekly updates on Obesity
#ObesityResearch #GLP1 #NovoNordisk #EliLilly #AstraZeneca #WeightLossDrugs #ClinicalTrials #HealthTech #BiotechNews #LucidQuest #ObesityPipeline #PharmaInnovation #MetabolicHealth #ObesityTreatment